The release of new book "big data of China's pharmaceutical R & D in the past 40 years"
Time of Update: 2019-07-01
New book release of China Pharmaceutical R & D 40 years big data interpretation industry 40 years storm purchase consultation: Zhang Jiaqing, mobile phone: 15123085574 (same
In 2018, Sansheng pharmaceutical's R & D investment increased by more than 40%, with multiple products under research
Time of Update: 2019-03-22
On March 20, 2019, China's leading biopharmaceutical company Sansheng Pharmaceutical (01530
HK) today announced its annual performance in 2018, which shows
Lu Tao: China's pharmaceutical R & D trend in the past 40 years of reform and opening up
Time of Update: 2018-06-11
From June 29, 2018 to June 30, 2018, under the guidance of China Pharmaceutical University, Chongqing Municipal Economic and Information Commission, sponsored by pharma.com
Notice of the editorial board meeting of the blue book of Chinese pharmaceutical R & D in the 40 years of reform and opening up
Time of Update: 2018-04-09
Executive editor of the blue book of China's pharmaceutical research and development in the past 40 years of reform and opening up Li Tianquan specifically introduced the preparation division of work and the requirements of the preparation content; 2.
Over the past year, the global R & D line of bio generic drugs has expanded by 40%
Time of Update: 2014-05-04
Source: Ding Xiangyuan's research data from decision resources on May 4, 2014 shows that in the past 12 months, the number of biosimilars development projects publicly disclosed in the world has increased by 40%.